Document Detail


siRNA delivery: from basics to therapeutic applications.
MedLine Citation:
PMID:  23276909     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The chance to selectively intervene and stop the development of any gene-dependent disease in different organs and pathologies makes siRNA an ideal therapeutic agent. However, serious issues should be addressed before the real therapeutic use of siRNA. The poor pharmacokinetic properties of siRNA, its short half-life, its low in vivo stability, its fast elimination by kidney filtration and its low transfection efficiency complicate the use of siRNA as a therapeutic molecule. In this review, we will describe the latest and most advanced approaches and strategies undertaken to address these limitations and improve siRNA delivery and its gene silencing efficacy as well as the prospects for its therapeutic applications.
Authors:
Tiziana Musacchio; Vladimir P Torchilin
Related Documents :
16890549 - Human spontaneous labor without histologic chorioamnionitis is characterized by an acut...
16786399 - Optimized rt-pcr method for assaying expression of monocyte chemotactic protein type 1 ...
17156879 - Transcarboxylase mrna: a marker which evidences p. freudenreichii survival and metaboli...
15681479 - Reliable transcript quantification by real-time reverse transcriptase-polymerase chain ...
16765639 - Detection of hpv in norwegian cervical biopsy specimens with type-specific pcr and reve...
8635199 - Luminescence-based systems for detection of bacteria in the environment.
17786629 - Regulation of the rat glutathione s-transferase a2 gene by glucocorticoids: crosstalk t...
24448659 - Expression of micrornas and their targets regulates floral development in tobacco (nico...
20351289 - Attenuation of forkhead signaling by the retinal determination factor dach1.
Publication Detail:
Type:  Journal Article; Review     Date:  2013-01-01
Journal Detail:
Title:  Frontiers in bioscience (Landmark edition)     Volume:  18     ISSN:  1093-4715     ISO Abbreviation:  Front Biosci (Landmark Ed)     Publication Date:  2013  
Date Detail:
Created Date:  2013-01-01     Completed Date:  2013-06-12     Revised Date:  2013-07-29    
Medline Journal Info:
Nlm Unique ID:  101612996     Medline TA:  Front Biosci (Landmark Ed)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  58-79     Citation Subset:  IM    
Affiliation:
Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, 360 Huntington Ave, Boston, MA 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
DNA-Directed RNA Polymerases / metabolism
Drug Delivery Systems / methods
Drug Stability
Humans
Micelles
Nanoparticles / administration & dosage
Polyethylene Glycols / administration & dosage
RNA Interference
RNA, Messenger / antagonists & inhibitors
RNA, Small Interfering / administration & dosage,  therapeutic use*
Viral Proteins / metabolism
Chemical
Reg. No./Substance:
0/Micelles; 0/Polyethylene Glycols; 0/RNA, Messenger; 0/RNA, Small Interfering; 0/Viral Proteins; EC 2.7.7.-/bacteriophage T7 RNA polymerase; EC 2.7.7.6/DNA-Directed RNA Polymerases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Steps of the coupled charge translocation in the catalytic cycle of cytochrome c oxidase.
Next Document:  Association between polymorphism of the NQO1, NOS3 and NFE2L2 genes and AMD.